NCHC

National Coalition On Health Care

  • About Us
    • Members and Supporters
    • Board of Directors
    • Staff
    • Annual Reports
  • Policy
    • COVID-19 Response
    • Make Prescription Drugs More Affordable
    • Eliminate Surprise Medical Billing
    • Make Health Care Affordable and Accessible
    • Promote a High-Value Health Care System that Supports Vulnerable Populations
  • Blog
  • Events
  • Newsroom
    • Press Releases
    • NCHC In The News
    • Policy Correspondence
    • Fact Sheets & Issue Briefs
  • Get Involved
    • Become a Member
    • Become a Funder
    • Career Opportunities & Internships
  • Contact Us

NCHC, Stakeholders Counter Attempt to Cripple Competition from Generic Biologic Drugs

October 2, 2012 By Larry McNeely

Tweet
Share

June 5, 2012

Contact: Cristina Flores

202-638-7151

NCHC, Stakeholders Counter Attempt to Cripple Competition from Generic Biologic Drugs

Washington, D.C. (June 5, 2012) – In a letter to U.S. Food and Drug Administration Commissioner Margaret Hamburg, health care advocates, seniors groups, unions, pension funds, consumer advocates, and health plans joined with the National Coalition on Health Care to urge the FDA to reject recent efforts to limit generic competition to high-cost biologic prescription drugs.

The letter was a response to comments from several pharmaceutical manufacturers submitted to the FDA that call for assigning generic biologic drugs a different International Nonproprietary Name (INN) from that belonging to the original brand name drug. The impact of this regulatory change could extend beyond FDA rules; several state prescribing laws require that generics can only be substituted for a brand name drug if they have the same name.

“This seemingly obscure regulatory decision could seriously impact the affordability of prescription drugs.  In these states, consumers and health plans would continue to face costs that can exceed $100,000 a year per person for a single brand-name drug,” explains NCHC President and CEO John Rother.

The letter also stressed significant negative implications for patient safety.

“Requiring different INNs for biologics and biosimilars could lead to patient and prescriber confusion, increasing the possibility of medication errors, and would also effectively separate the biosimilar from existing safety information about the underlying molecule,” the letter states.  “In addition, since adverse events and product recalls for small-molecule and biologic drugs are already successfully identified using the national drug code and lot number, there is no compelling evidence that biosimilars should be handled differently.”

“With high drug costs, driven by the high price of biologics,  burdening consumers, businesses and public institutions alike,  a competitive market for these drugs is vital for both our health system and the national economy,” said Rother.

Signatories to the letter included the National Coalition on Health Care, Health Care for America Now, AARP, Aerospace and Agricultural Implement Workers of America (UAW), Alliance for Retired Americans, AFL-CIO, American Federation of Federal, State, County and Municipal Employees (AFSCME), American Federation of Teachers (AFT), American Medical Students Association, Blue Cross and Blue Shield Association, California Public Employees Retirement System, Community Catalyst, Consumer Federation of America (CFA), International Brotherhood of Teamsters, National Association of Chain Drug Stores (NACDS), National Committee to Preserve Social Security and Medicare, Older Women’s League, Service Employees International Union (SEIU), United Automobile, UAW Retiree Medical Benefits Trust, United Steelworkers (USW), US Action, and US PIRG.

Documents:

June 5 – FDA Letter

Letter from Consumers to FDA on INN June 4 2012

Filed Under: Uncategorized

NCHC, Stakeholders Counter Attempt to Cripple Competition from Generic Biologic Drugs

June 5, 2012 By Larry McNeely

June 5, 2012

In a letter to U.S. Food and Drug Administration Commissioner Margaret Hamburg, health care advocates, seniors groups, unions, pension funds, consumer advocates, and health plans joined with the National Coalition on Health Care to urge the FDA to reject recent efforts to limit generic competition to high-cost biologic prescription drugs. The letter was a response to comments from several pharmaceutical manufacturers submitted to the FDA that call for assigning generic biologic drugs a different International Nonproprietary Name (INN) from that belonging to the original brand name drug.

View full press release

Filed Under: Press Releases Tagged With: Press Releases

Mission

To bring together key stakeholders in order to achieve an affordable, high-value health care system for patients and consumers, for employers and other payers, and for taxpayers.

Signup for NCHC Newsletter

NCHC Recent Policy Correspondence

  • NCHC STATEMENT ON BICAMERAL AND BIPARTISAN SURPRISE BILLING LEGISLATION, “NO SURPRISES ACT,”
  • NCHC STATEMENT ON PART D REBATE SAFE HARBOR REPEAL AND “MOST FAVORED NATION” DEMONSTRATION
  • NCHC Statement On The Trump Administration’s “Most-Favored-Nation” Drug Pricing Executive Order
  • NCHC Statement on the Trump Administration’s Executive Orders
  • NCHC Statement on the Pricing of Remdesivir
...More Policy Correspondence

National Coalition on Health Care

About Us

The National Coalition on Health Care (NCHC) was formed more than two decades ago to help achieve comprehensive health system change and is currently led by John Rother. We aim to be a leader in promoting a healthy population and a more effective, efficient and responsive health system that provides quality care for all. NCHC is a nonpartisan, nonprofit organization of organizations. Our growing Coalition represents more than 80 participating organizations, including medical societies, businesses, unions, health care providers, faith-based associations, pension and health funds, insurers, and groups representing consumers, patients, women, … Read More...

PRESIDENT

John Rother

Interim CEO

Shawn Martin

CHAIRMAN

Jack Lewin
Principal and Founder
Lewin and Associates, LLC

MISSION

To bring together key stakeholders in order to achieve an affordable, high-value health care system for patients and consumers, for employers and other payers, and for taxpayers.

CONTACT US

900 16th Street NW, Suite 400
Washington, DC 20006
contactus@nchc.org

Connect With NCHC

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Recent News & Posts

  • NCHC Letter to President-Elect Biden’s Transition Team
  • NCHC STATEMENT ON BICAMERAL AND BIPARTISAN SURPRISE BILLING LEGISLATION, “NO SURPRISES ACT,”
  • The Impact of COVID-19 on Communities of Color
  • NCHC Statement On CMS’ “Geographic Direct Contracting” Model
  • NCHC STATEMENT ON PART D REBATE SAFE HARBOR REPEAL AND “MOST FAVORED NATION” DEMONSTRATION

Recent Tweets

Tweets by NC_HC

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in